Clinical Venture Services 7 September, 2018

Science business Clinical Venture Services (CVS), based at Discovery Park, has pioneered a potentially life-changing trial which uses a device-based solution as an alternative to lifelong drug treatment for managing high blood pressure.

The start-up company, which moved to Discovery Park last year, was contracted by medical device company, ReCor Medical to run a study to explore how the device could improve the condition.

The device requires a short operation and uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry the signal controlling blood pressure.

Helen Reeve-Stoffer, owner of CVS and acting head of Clinical Affairs for ReCor Medical, said: “This trial is potentially ground-breaking and the fact that we could help so many patients is really impressive. Our research found that many people fail to take their medication, and so this device may give people another option if they don’t want to, or are unable to, take medicine. It’s still very early in the evaluation of this therapy, but the opportunity to have an alternative to drugs is massively significant to the blood pressure community.”

When we were consenting patients for the trial, we struggled using the usual methods of recruiting through the hospitals. So instead, we tried doing something pretty cutting edge – using traditional and social media. We ended up with thousands of applications, of which approximately 800 were consented. It was an amazing result.”

“Discovery Park has been fundamental in supporting us to host such an important study in the history of medical devices. We only moved here in July 2017, but the pace at which things have accelerated since then has been huge.

“It’s so much more productive than the home office I was working in before. Also, we’ve really benefited from the collaborative environment on the park – we’ve used a lot of the services here and found that everything we needed to support our work is based here. It’s been a very positive experience.”

Subscribe to our mailing list

To sign up to our Mailing List, please click on the button below

Subscribe

Twitter iconTweets